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Loss of BMPR2 expression in skeletal progenitor cells 
reduces age-related bone loss 
 
Michael S. Eaton1, Aaron M. Hudnall1, Jordan B. Newby1, 2, Vicki Rosen3, Jonathan W. Lowery1 
 
1Department of Biomedical Science, Marian University College of Osteopathic Medicine; 2Department of Biology, Freed-Hardeman University; 
3Department of Developmental Biology, Harvard School of Dental Medicine 
Osteoporosis is a disease of low bone mineral density (BMD) that affects 10 million Americans and accounts for 1.5 million 
fractures annually. With an additional 34 million Americans at risk for developing the disease, osteoporosis is both a 
significant health problem and a considerable socioeconomic burden. Current first-line therapies for osteoporosis involve 
anti-resorptive agents but many patients, such as those with drastically low BMD or high fracture risk, would benefit from 
augmenting bone formation as well as inhibiting bone loss. We recently reported that targeted deletion of the type 2 BMP 
receptor BMPR2 in skeletal progenitor cells of the limb bud using Prx1-Cre (Bmpr2 mutant  mice) leads to dramatically 
increased bone mass and bone formation rate by ten weeks of age in the absence of changes in osteoclast number or 
function (Lowery et al., Journal of Cell Science 2015). In the present study, we examined the impact of Bmpr2 deletion on 
age-related bone loss in Bmpr2 mutant mice. Consistent with our previous results, 55-week-old female Bmpr2 mutant mice 
exhibit approximately four-fold higher bone mass in the tibia than control mice. Moreover, the age-related decline in bone 
mass from 15 weeks to 55 weeks of age in female Bmpr2 mutant mice is reduced 1.8-fold (CI, 1.5-2.2) compared to control 
mice. Bone mass of the L5 vertebrae, which is outside the Prx1-Cre expression domain, is unchanged in Bmpr2 mutant mice 
compared to control mice at all ages examined. Quantification of the serum bone turnover markers Procollagen Type I N-
terminal Propeptide (PINP) and Collagen Type I C-telopeptide (CTx) suggest that high bone mass in aging female Bmpr2 
mutant mice is preserved due to a sustained increase in bone formation rate to at least 35 weeks of age with no alteration 
in bone resorption. Collectively, our findings provide insight into the mechanisms regulating age-related bone loss and 
suggest that strategies aimed at controlling signaling through BMPR2 have the potential to impact bone mass in the aging 
adult skeleton. 
Fig. 1 Conditional deletion of Bmpr2 in skeletal 
progenitors leads to high bone mass by ten weeks-
of-age due to elevated individual osteoblast 
activity level. A: At left, Bmpr2 mutant mice were 
generated by crossing Bmpr2fl/fl; Prx1-Cre+ males 
with Bmpr2fl/fl females (Lowery et al., Journal of Cell 
Science 2015). At middle, Prx1-Cre causes efficient 
deletion in the mesoderm of the appendicular 
skeleton by embryonic day 9.5 as evidenced by 
reporter staining in the forelimb (blue staining; 
adapted from Logan et al., Genesis 2002). At right, 
the resulting truncated Bmpr2 transcript is 
confirmed by RT-PCR in RNA from 15-week-old 
humerii (Lowery et al., Journal of Cell Science 2015). 
B, C: As previously reported (Lowery et al., Journal 
of Cell Science 2015), osteoblast density (B) using 
standard analysis of number of osteoblasts per mm 
of bone perimeter (N.Ob/B.Pm (/mm)) and bone 
formation rate (C, BFR) using standard analysis of 
BFR relative to bone surface (BFR/BS) in ten-week-
old female mice.  
Fig. 2 Reduced age-related decline in bone mass of female Bmpr2 mutant mice. A, B: Representative histology of 
tibiae from 55-week-old female control (A) and Bmpr2 mutant (B) mice. C-F: Trabecular (C-D) and mid-shaft (E-F) 
volumetric bone mineral density (vBMD) quantified by micro-CT in tibiae of females control and Bmpr2 mutant mice at 
55 weeks of age (C, E) and change between 15 and 55 weeks of age (D, F). G-H: Volumetric bone mineral density 
(vBMD) quantified by micro-CT in L5 vertebrae, which is outside of the Prx1-Cre expression domain, of females control 
and Bmpr2 mutant mice at 55 weeks of age (G) and change between 15 and 55 weeks of age (H). 
Conclusions: 
- Loss of Bmpr2 in embryonic skeletal progenitor cells leads to high bone mass due to 
increased osteoblast activity 
- Bmpr2 mutant mice exhibit high bone mass to at least 55 weeks of age and experience 
reduced age-related bone loss 
- Markers of bone formation rate are elevated to at least 35 weeks of age in Bmpr2 mutant 
mice with no observed change in bone resorption parameters at any age examined 
 
Current and Future Directions: 
- Examination of signal transduction changes associated with loss of BMPR2 in the aging 
skeleton using western blot and immunohistochemistry 
- Identification and characterization of the gene signature associated with sustained 
increase in bone formation in the absence of BMPR2 expression in the aging skeleton 
using RNA-Seq and qRT-PCR 
- Development of non-genetic means to reduce BMPR2 function and/or expression in the 
postnatal skeleton 
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Fig. 3 Sustained increase in bone formation rate in Bmpr2 mutant mice with 
no defect in bone resorption rate. A, B: Quantification of the bone formation 
marker PINP (A) and the bone resoprtion marker CTx (B) in sera of female 
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